65,437 trials
Cervical Adenocarcinoma · Cervical Adenosquamous Carcinoma · Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Primary: Objective Tumor Response — 0.071 proportion
Brain and Central Nervous System Tumors · Extragonadal Germ Cell Tumor · Ovarian Cancer
Primary: Progression-free Survival — 11.8 Months
Rheumatoid Arthritis
Primary: Change From Baseline in Disease Activity Score 28 - Erythrocyte Sedimentation Rate (DAS28-ESR) Score in the Full Analysis Set (FAS) — 5.55; -3.24 Units on a scale
Contrast Induced Nephropathy (CIN)
Primary: Primary Effectiveness Endpoint — 76; 75 Participants
Myopia · Astigmatism
Primary: Lens Surface Assessment of Study Lenses - Surface Wettability — 3.4; 3.4; 3.4; 3.4 units on a scale
Type 2 Diabetes
Primary: Assessment of Glycemic Control (HbA1c) Over Time — 8.7; 6.7; 6.9; 6.9 HbA1c %
Pediatric Obesity
Primary: Change in BMI and Percentage Fat Mass Standard Deviation Scores After One Year of Treatment With Metformin or Placebo — -0.370; -0.22; -0.139; -0.065 Z score
Neovascular Age-related Macular Degeneration
Primary: Average Best-corrected Visual Acuity (BCVA) (Letters) Change up to Month 12 — 0.1; 1.0 Letters correctly read
ISCHEMIC CARDIOMYOPATHY
Primary: COMPARISON OF MYOCARDIAL INFARCTION SIZE MEASUREMENTS USING INVESTIGATIONAL MANGANESE-ENHANCED MRI (MEMRI) OR DELAYED GADOLINIUM ENHANCED MRI (DEMRI) — 41; 18.25…
Sepsis · Systemic Inflammatory Response Syndrome
Primary: Total Fluid (ml/kg/Day) Given — 124.38; 122.099 ml/kg/day
Secondary Hyperparathyroidism · Chronic Kidney Disease
Primary: Percent of Patients Achieving Parathyroid Hormone Target ≤ 300 — 21 percentage of subjects meeting target — p=< 0.05
Autism · Asperger's Disorder · Pervasive Developmental Disorder
Primary: Clinical Global Impressions-Improvement — 1.8 units on a scale
Tobacco Use Disorder · Nicotine Addiction
Primary: Point-prevalence Abstinence at End of Treatment — 38; 43 Percentage of participants — p=0.14
Age Related Macular Degeneration
Primary: The Number of Patients With no Fluid on OCT — 10 participants
Amyotrophic Lateral Sclerosis
Primary: Hours of NIPPV Usage — 49.94; 45.75 hours